Brief: ABVC Biopharma Announces Principal Investigator Meeting For Phase Ii Part 2 Adhd Clinical Study
02/02/2022 13:01
Feb 2 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA ANNOUNCES PRINCIPAL INVESTIGATOR MEETING
FOR
PHASE II PART 2 ADHD CLINICAL STUDY
* ABVC BIOPHARMA INC - PRINCIPAL INVESTIGATOR MEETING FOR
ABV-1505
PHASE II PART 2 ADHD CLINICAL STUDY WILL BE HELD ON FEBRUARY 14,
2022
Source text for Eikon: ID:nGNX5XV4rt
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner